Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of “Hold” by Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has earned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $62.1667.

Several research analysts have weighed in on SUPN shares. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $50.28, for a total value of $2,514,000.00. Following the transaction, the vice president directly owned 17,044 shares of the company’s stock, valued at $856,972.32. The trade was a 74.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Georges Gemayel sold 10,000 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $53.71, for a total transaction of $537,100.00. Following the completion of the transaction, the director directly owned 28,159 shares in the company, valued at $1,512,419.89. This represents a 26.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 120,881 shares of company stock worth $6,139,356. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in SUPN. Jefferies Financial Group Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 62.0% during the 3rd quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company’s stock worth $4,118,000 after acquiring an additional 32,979 shares during the period. Phocas Financial Corp. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $4,042,000. Tudor Investment Corp ET AL acquired a new stake in shares of Supernus Pharmaceuticals during the third quarter worth approximately $1,434,000. Ruffer LLP acquired a new position in Supernus Pharmaceuticals in the third quarter worth $2,647,000. Finally, Teacher Retirement System of Texas boosted its holdings in Supernus Pharmaceuticals by 648.9% in the third quarter. Teacher Retirement System of Texas now owns 112,638 shares of the specialty pharmaceutical company’s stock worth $5,383,000 after purchasing an additional 97,597 shares during the period.

Supernus Pharmaceuticals Trading Down 3.5%

Supernus Pharmaceuticals stock opened at $49.43 on Friday. Supernus Pharmaceuticals has a 12-month low of $30.83 and a 12-month high of $59.68. The stock has a market cap of $2.87 billion, a P/E ratio of -96.92, a PEG ratio of 1.10 and a beta of 0.57. The company has a 50-day moving average price of $50.53 and a 200 day moving average price of $49.90.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.